Market Overview

UPDATE: Deutsche Bank Reiterates Hold Rating, Lowers PT on Akorn

Related AKRX
Benzinga's Top Upgrades
Drug Price Hike Concerns Spill Over Into Other Pharma Stocks

In a report published Wednesday, Deutsche Bank reiterated its Hold rating on Akorn (NASDAQ: AKRX), but slightly lowered its price target from $14.00 to $13.00.

Deutsche Bank noted, “Q3 EPS A Penny Better– Benefiting from Lower R&D, Higher Gross Margin. Akorn reported Q3 cash EPS of $0.14, a penny ahead of both our and consensus ests, primarily due to modestly lower than forecasted R&D expenses (-$1.3M) and slightly better than projected gross margin of 57.6% (+80 bp vs our est). Nonetheless, while mgt continues to execute nicely on its plan, we maintain our HOLD rating on the co's shares in part due to our below consensus EPS ests for 2013 and 2014 and a valuation (5.4x 2012 revs) which still appears too ‘rich' for consolidators.”

Akorn closed on Tuesday at $12.38.

Latest Ratings for AKRX

Sep 2016PiperJaffrayUpgradesNeutralOverweight
Aug 2016Deutsche BankDowngradesBuyHold
Aug 2016Raymond JamesDowngradesOutperformMarket Perform

View More Analyst Ratings for AKRX
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings


Related Articles (AKRX)

View Comments and Join the Discussion!